Overcoming Resistance and Toxicity Hurdles: PST’s Localized Drug Delivery Technology May Unlock Combined MEK/mTOR Inhibition For Multiple KRAS+ Tumors Types

IRVINE, Calif., May 23, 2024 /PRNewswire/ — Postsurgical Therapeutics, Inc. (PST) today announced the successful completion of an in vivo study of its proprietary injectable gel formulation containing two drugs used to treat several types of KRAS mutated solid tumors. The results…